Combination treatment for chronic lymphocytic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of an oral targeted therapy and a short course of chemotherapy for patients with previously untreated chronic lymphocytic leukemia (CLL). The goal is to control the disease and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with CLL and meet standard criteria for starting treatment.
- Your CLL must not have certain high-risk genetic changes (deletion of chromosome 17p or TP53 mutation).
- You are generally healthy and able to perform daily activities (ECOG score 0-2).
- You have adequate kidney and liver function.
- You have not had major surgery in the last 30 days.
- You are not pregnant or breastfeeding, and you agree to use effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, pirtobrutinib (a pill) and obinutuzumab (an infusion), given for a set period of time in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had any previous treatment for their disease. The goal is to see if this combination can control the cancer effectively.
This trial tests a three-drug combination for people who have not yet had treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to improve outcomes with a targeted, mostly oral regimen.
This trial tests two drugs, pirtobrutinib and epcoritamab, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after at least one previous treatment. The goal is to see if this combination can help control the disease.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and bendamustine) as a first treatment for chronic lymphocytic leukemia (CLL). The goal is to see if this combination is safe and effective for people who have not yet received any treatment for CLL.
This trial tests two oral medications (sonrotoclax and zanubrutinib) for people newly diagnosed with CLL or SLL who need treatment. The goal is to see if this combination is effective and safe.
Hear when a new CLL (Chronic Lymphocytic Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.